Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Nextech leads Revolution Medicines' $56M series B

April 24, 2018 1:59 PM UTC

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column Group and Third Rock Ventures.

This year, the company plans to start a clinical trial of lead candidate RMC-4630, a Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitor to treat solid tumors...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article